Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

Bringing business risk into sharp focus

Nature Biotechnology volume 30, pages 30–32 (2012)Cite this article

Subjects

Abstract

Comprehensive due diligence on research constraints, regulatory and reimbursement barriers, as well as patient and physician preferences is important to increase the chances of success for a life science business.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Bill Gruber is CEO at Solace Therapeutics, Framingham, Massachusetts, USA.,

    Bill Gruber

  2. Emily Walsh is principal consultant, Halloran Consulting Group, Waltham, Massachusetts, USA.,

    Emily Walsh

Authors
  1. Bill Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily Walsh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gruber, B., Walsh, E. Bringing business risk into sharp focus. Nat Biotechnol 30, 30–32 (2012). https://doi.org/10.1038/nbt.2081

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2081

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research